1. Home
  2. SLS vs LICY Comparison

SLS vs LICY Comparison

Compare SLS & LICY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLS
  • LICY
  • Stock Information
  • Founded
  • SLS 2012
  • LICY 2016
  • Country
  • SLS United States
  • LICY Canada
  • Employees
  • SLS N/A
  • LICY N/A
  • Industry
  • SLS Biotechnology: Pharmaceutical Preparations
  • LICY Environmental Services
  • Sector
  • SLS Health Care
  • LICY Industrials
  • Exchange
  • SLS Nasdaq
  • LICY Nasdaq
  • Market Cap
  • SLS 75.3M
  • LICY 83.8M
  • IPO Year
  • SLS N/A
  • LICY N/A
  • Fundamental
  • Price
  • SLS $1.32
  • LICY $2.08
  • Analyst Decision
  • SLS Buy
  • LICY Hold
  • Analyst Count
  • SLS 1
  • LICY 1
  • Target Price
  • SLS $3.00
  • LICY $6.00
  • AVG Volume (30 Days)
  • SLS 753.9K
  • LICY 2.4M
  • Earning Date
  • SLS 11-13-2024
  • LICY 11-07-2024
  • Dividend Yield
  • SLS N/A
  • LICY N/A
  • EPS Growth
  • SLS N/A
  • LICY N/A
  • EPS
  • SLS N/A
  • LICY N/A
  • Revenue
  • SLS N/A
  • LICY $27,400,000.00
  • Revenue This Year
  • SLS N/A
  • LICY $48.13
  • Revenue Next Year
  • SLS N/A
  • LICY $18.15
  • P/E Ratio
  • SLS N/A
  • LICY N/A
  • Revenue Growth
  • SLS N/A
  • LICY N/A
  • 52 Week Low
  • SLS $0.50
  • LICY $1.22
  • 52 Week High
  • SLS $1.72
  • LICY $15.36
  • Technical
  • Relative Strength Index (RSI)
  • SLS 60.02
  • LICY 45.46
  • Support Level
  • SLS $1.22
  • LICY $2.69
  • Resistance Level
  • SLS $1.39
  • LICY $4.98
  • Average True Range (ATR)
  • SLS 0.08
  • LICY 0.57
  • MACD
  • SLS 0.02
  • LICY -0.07
  • Stochastic Oscillator
  • SLS 72.00
  • LICY 11.95

About SLS SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

About LICY Li-Cycle Holdings Corp.

Li-Cycle Holdings Corp is a lithium-ion battery resource recovery and lithium-ion battery recycler. The company's proprietary process Spoke and Hub recycling process is designed at its Spokes, to process battery manufacturing scrap and end-of-life batteries to produce black mass and other intermediate products, and at its Hubs, to process black mass to recover raw materials, including but not limited to lithium carbonate, cobalt sulphate, and nickel sulphate.

Share on Social Networks: